Linked Life Data

7751519

Source:http://linkedlifedata.com/resource/pubmed/id/7751519

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5 Pt 1
pubmed:dateCreated
1995-6-22
pubmed:abstractText
We have studied the effect of a nonsedating antihistamine, cetirizine dihydrochloride, on the in vitro chemotaxis of leukocytes from human peripheral blood. We observed that 0.25 microgram/ml of cetirizine dihydrochloride in vitro significantly inhibited the chemotaxis of monocytes toward N-formyl-methionyl-leucyl-phenylalanine and leukotriene B4. Higher concentrations of cetirizine, 1.0 and 2.5 micrograms/ml, completely inhibited monocyte chemotaxis without affecting cell viability. T-lymphocyte migration was also significantly depressed but not abolished. Pyrilamine (mepyramine) was not inhibitory in equimolar concentrations. According to these in vitro observations, we extended our studies to measure monocyte and T-lymphocyte chemotaxis in an open study, where four healthy volunteers and six patients with atopic dermatitis took 10 and 20 mg/day cetirizine 3 days. We observed a reduction in ex vivo monocyte and T-lymphocyte chemotaxis toward N-formyl-methionyl-leucyl-phenylalanine and leukotriene B4 without a reduction of the blood cell count. The results were confirmed in an ensuing double-blind, placebo-controlled study of 16 healthy subjects and 14 adult patients with atopic dermatitis, where ex vivo monocyte chemotaxis was reduced or abolished during cetirizine therapy. Serum levels of the two eosinophil-derived granule proteins, eosinophilcationic protein P and eosinophil protein X, were not changed during the treatment period of 7 days. The results show that cetirizine dihydrochloride has an inhibitory effect on monocytes and T lymphocytes in vitro and ex vivo. Our findings support the clinical observations that cetirizine dihydrochloride has an antiinflammatory effect besides its H1-blocking activity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0091-6749
pubmed:author
pubmed:issnType
Print
pubmed:volume
95
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
979-86
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:7751519-Anti-Inflammatory Agents, Non-Steroidal, pubmed-meshheading:7751519-Blood Proteins, pubmed-meshheading:7751519-Cetirizine, pubmed-meshheading:7751519-Chemotaxis, Leukocyte, pubmed-meshheading:7751519-Dermatitis, Atopic, pubmed-meshheading:7751519-Dose-Response Relationship, Drug, pubmed-meshheading:7751519-Double-Blind Method, pubmed-meshheading:7751519-Eosinophil Granule Proteins, pubmed-meshheading:7751519-Humans, pubmed-meshheading:7751519-Leukocytes, Mononuclear, pubmed-meshheading:7751519-Leukotriene B4, pubmed-meshheading:7751519-Monocytes, pubmed-meshheading:7751519-N-Formylmethionine Leucyl-Phenylalanine, pubmed-meshheading:7751519-Placebo Effect, pubmed-meshheading:7751519-Pyrilamine, pubmed-meshheading:7751519-Ribonucleases, pubmed-meshheading:7751519-T-Lymphocytes
pubmed:year
1995
pubmed:articleTitle
Cetirizine inhibits the in vitro and ex vivo chemotactic response of T lymphocytes and monocytes.
pubmed:affiliation
Department of Dermatology, Marselisborg Hospital, Aarhus C., Denmark.
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial, Research Support, Non-U.S. Gov't